Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
RSS

Pegylated interferon proves superior to standard interferon for treatment of HCV

Nov. 16, 1998

Data presented at AASLD indicate role for caspase inhibitors in liver transplantation

Nov. 16, 1998

Antiulcer tetrahydropyrido compounds in development at Byk Gulden

Nov. 16, 1998

Bristol-Myers Squibb initiates phase III HBV clinical trials; phase II data reported

Nov. 13, 1998

Heptazyme demonstrates potent activity against HCV

Nov. 12, 1998

KGF-2 shows promise for treating IBD

Nov. 12, 1998

Inhibition of cytokine production contributes to the antiinflammatory activity of orazipone

Nov. 11, 1998

Proton pump inhibitors in the pipeline at Yuhan

Nov. 11, 1998

Enzyme formulation for pancreatic insufficiency enters preclinical development at Altus

Nov. 5, 1998

Zadaxin plus famciclovir provides surprising synergistic efficacy against HBV

Nov. 5, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...